59.94
前日終値:
$60.31
開ける:
$58.39
24時間の取引高:
4.42M
Relative Volume:
1.68
時価総額:
$11.52B
収益:
$2.95B
当期純損益:
$523.88M
株価収益率:
22.28
EPS:
2.69
ネットキャッシュフロー:
$620.18M
1週間 パフォーマンス:
+4.88%
1か月 パフォーマンス:
+3.86%
6か月 パフォーマンス:
+5.42%
1年 パフォーマンス:
-8.99%
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
名前
Biomarin Pharmaceutical Inc
セクター
電話
(415) 506-6700
住所
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical Inc
|
59.94 | 11.59B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-20 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | ダウングレード | Stifel | Buy → Hold |
| 2025-09-08 | 開始されました | H.C. Wainwright | Neutral |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-24 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-30 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-20 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 開始されました | Evercore ISI | Outperform |
| 2023-11-15 | 開始されました | Wells Fargo | Overweight |
| 2023-10-23 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 開始されました | Raymond James | Mkt Perform |
| 2023-09-18 | 開始されました | UBS | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2023-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 開始されました | Citigroup | Neutral |
| 2023-01-30 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2022-10-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2022-04-25 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-09 | アップグレード | Stifel | Hold → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-04 | 再開されました | Guggenheim | Buy |
| 2021-03-01 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-08-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-08-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | ダウングレード | Stifel | Buy → Hold |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 繰り返されました | Citigroup | Buy |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-24 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-04-09 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 繰り返されました | Stifel | Buy |
| 2018-08-03 | 繰り返されました | Stifel | Buy |
すべてを表示
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
Looking To Compete With BioMarin, Ascendis Continues Its Growth Story - Citeline News & Insights
BioMarin Raises $850 Million Notes for Amicus Acquisition - TipRanks
BioMarin Signs Indenture For Senior Notes With U.S. Bank Trust Company - TradingView
BioMarin finances Amicus acquisition with $850M notes and new loans - Stock Titan
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Baird maintains BioMarin stock rating amid competitor’s positive trial data By Investing.com - Investing.com India
Baird maintains BioMarin stock rating amid competitor’s positive trial data - Investing.com
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - bitget.com
Pharma companies left out of Trump's drug-pricing deals look for way in - marketscreener.com
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline - Finviz
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Biomarin receives Health Canada notice of compliance with conditions for Voxzogo, for achondroplasia - marketscreener.com
BioMarin Pharmaceutical (BMRN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Acquisition plans to fuel BioMarin Pharmaceutical (BMRN), according to Barclays - MSN
What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? - Finviz
BioMarin Pharmaceutical Stock Outlook Looks Promising - Intellectia AI
BioMarin’s Strategic Acquisition Nears Critical Data Readout - AD HOC NEWS
Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays - Finviz
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Momentum - Sahm
Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $84.00 at Piper Sandler - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Callan Family Office LLC Has $2.27 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Achondroplasia Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi - Barchart.com
AlphaQuest LLC Sells 21,696 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Sues Zydus to Block Copy of Dwarfism Drug Voxzogo - Bloomberg Law News
BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook on a Biotech Leader with 60% Upside Potential - DirectorsTalk Interviews
BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
(BMRN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Federated Hermes Inc. - MarketBeat
Investors Holding Back On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛
Should You Buy BioMarin Pharmaceutical Before Feb. 18? - Finviz
BioMarin prices $850 million in senior notes to fund Amicus acquisition - Investing.com India
BioMarin Secures Major Debt Financing for Amicus Acquisition - TipRanks
BioMarin Pharmaceutical Inc Announces Pricing of Senior Notes and Loan Syndication - TradingView
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility - Chartmill
Hussman Strategic Advisors Inc. Takes $1.14 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
BioMarin Weighs Amicus Deal And Billions In New Debt Financing - simplywall.st
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Barclays - MarketBeat
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) - Finviz
Assessing BioMarin Pharmaceutical (BMRN) Valuation As Investors Revisit The Rare Disease Specialist - Sahm
Double-digit Revenue Growth Till 2030 Drives BioMarin’s (BMRN) Bullish Thesis - Insider Monkey
Biomarin Pharmaceutical Inc (BMRN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):